Genmab A/S

GMABNASDAQHealthcare● Active

$25.15

+$0.42(+1.70%)

Market Cap$15.4B

P/E Ratio—

52W High$35.43

52W Low$20.225

Avg Volume1.8M

Open$24.73

Beta0.68

Free Cash Flow Financials Revenue

Genmab A/S (GMAB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

GMAB · free cash flow · updated Jun 8, 2026

Core FCF metrics

GMAB · FCF · TTM · margin & CAGR

Free cash flow was $1.15B for FY2025 (fiscal year ending 2025-12-31), down 84.8% year-over-year The FCF margin was 30.9%. Five-year CAGR stands at -28.4%.

FY2025 Free Cash Flow$1.15B▼ -84.8% YoY

Trailing 12M (TTM)$871.3Mtrailing 4 quarters sum

FCF Margin30.9%$1.15B ÷ revenue

3-Year CAGR-31.6%FY2022 → FY2025

5-Year CAGR-28.4%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

GMAB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.19B(37M)$1.15B▼ 84.8%30.9%

FY2024$7.77B(187M)$7.58B▲ +8.3%35.2%

FY2023$7.38B(376M)$7.00B▲ +94.8%42.5%

FY2022$3.91B(317M)$3.60B▲ +81.9%24.8%

FY2021$2.23B(252M)$1.98B▼ 67.7%23.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

GMAB · P/FCF · FCF yield · FCF per share

Genmab A/S (GMAB) trades at a FCF yield of 5.68% and a price-to-free-cash-flow ratio of 18.0x. FCF per share stands at $1.40, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

5.68%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.40

TTM FCF ÷ Shares Outstanding

Price / FCF

x18.0

Share Price ÷ FCF per Share

EV / FCF (TTM)

x22.0

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

GMAB · cash flow statement · operating / investing / financing

For FY2025, Genmab A/S generated $1.19B in operating cash flow and spent 37M in capital expenditures, yielding $1.15B in free cash flow.

Operating Activities

+$1.19B

Cash from core business operations

2025-12-31

Investing Activities

−$5.65B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$4.79B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.19B) − |CapEx| (37M) = FCF ($1.15B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

GMAB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Genmab A/SYOU

GMAB

$1.15B-84.8%30.9%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Genmab A/S (GMAB) reported free cash flow of $1.15B for FY2025 (fiscal year ending 2025-12-31), down 84.8% year-over-year. The FCF margin was 30.9%.

Based on available data, Genmab A/S has maintained positive free cash flow for at least 13 fiscal year(s). FCF peaked at $7.58B in FY2024. The 5-year CAGR stands at -28.4%.

Genmab A/S's FCF yield is 5.68% and price-to-FCF ratio is 18.0x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

GMAB free cash flow · 8 questions

Genmab A/S free cash flow was $1.15B for FY2025, down 84.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $871.3M.

GMAB free cash flowGMAB FCFGMAB FCF 2025GMAB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Genmab A/S · Genmab A/S SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026